With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Editors: Story has been updated from original, with material from the president of the Arizona Obesity Organization. Slug: ...

Aging America may revive healthcare stocks after a rough year — discover why long-term trends point to a powerful rebound.

Oscar Health (NYSE: OSCR) built on its profitable start to 2025 with a strong first quarter, though emerging challenges in Q2 ...

The University of Pennsylvania is suing three leading insulin makers and companies that negotiate drug price deals for insurance plans, accusing them of a scheme to drive up prices of a medication ...

The global injectable drug delivery market is experiencing a significant transformation, poised to reach a staggering USD 113 ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...